Tumor necrosis factor

Endothelial Biomedicine

Volumn , Issue , 2007, Pages 261-265

  Pober, Jordan S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928853705     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511546198.032     Document Type: Chapter

References (42)

1. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975; 72:3666–3670.
2. Beutler B, Cerami A. The biology of cachectin/TNF – a primary mediator of the host response. Ann Rev Immunol. 1989; 7:625– 655.
3. Aggarwal BB, Kohr WJ, Hass PE, et al. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem. 1985; 260:2345–2354.
4. Aggarwal BB, Aiyer RA, Pennica D, et al.Humantumour necrosis factors: structure and receptor interactions. Ciba Found Symp. 1987; 131:39–51.
5. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985; 316:552–554.
6. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002; 27:19–26.
7. Korner H, Cook M, Riminton DS, et al. Distinct roles for lymphotoxin-alpha and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur J Immunol. 1997; 27:2600–2609.
8. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Ann Rev Med. 1994; 45:491– 503.
9. Neuhaus T, Totzke G, Gruenewald E, et al. Tumour necrosis factor-alpha gene expression and production inhumanumbilical arterial endothelial cells. Clin Sci (Lond). 2000; 98:461–470.
10. Debets JM, Kampmeijer R, van der Linden MP, et al. Plasma tumor necrosis factor andmortality in critically ill septic patients. Crit Care Med. 1989; 17:489–494.
11. Slowik MR, De Luca LG, Fiers W, Pober JS. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol. 1993; 143:1724–1730.
12. Bradley JR, Thiru S, Pober JS. Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells. Am J Pathol. 1994; 146:27–32.
13. D’Alessio D, Al-Lamki RS, Bradley JR, Pober JS. Caveolae participate in tumornecrosis factor receptor 1 signaling and internalization in ahumanendothelial cell line. Am J Pathol. 2005; 166:1273– 1282.
14. Wang J, Al-Lamki RS, Zhang H, et al. Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulatingTNFreceptor shedding from the cell surface and Golgi storage pool. J Biol Chem. 2003; 278:21751–21760.
15. Al-Lamki RS, Wang J, Vandenabeele P, et al. TNFR1-andTNFR2-mediated signaling pathways in human kidney are cell typespecific and differentially contribute to renal injury. FASEB J. 2005; 19:1637–1645.
16. Wallach D, Engelmann H, Nophar Y, et al. Soluble and cell surface receptors for tumor necrosis factor. Agents Actions Suppl. 1991; 35:51–57.
17. Wu H. Assembly of post-receptor signaling complexes for the tumor necrosis factor receptor superfamily. Adv Protein Chem. 2004; 68:225–279.
18. Darnay BG, Aggarwal BB. Early events in TNF signaling: A story of associations and dissociations. J Leukoc Biol. 1997; 61:559– 566.
19. Schmidt C, Peng B, Li Z, et al. Mechanisms of proinflammatory cytokine-induced biphasic NF-kappaB activation. Mol Cell. 2003; 12:1287–1300.
20. Hoeflich KP, Yeh WC, Tao Z, et al. Mediation of TNF receptor-associated factor effector functions by apoptosis signalregulating kinase-1 (ASK1). Oncogene. 1999; 18:5814–5820.
21. Zhang H, Zhang R, Luo Y, et al. AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. J Biol Chem. 2004; 279:44955–44965.
22. Micheau O, Tschopp J. Induction of TNF receptor 1-mediated apoptosis via two sequential signaling complexes. Cell. 2003; 114: 181–190.
23. Yin XM. Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res. 2000; 10:161–167.
24. Deng Y, Ren X, Yang L, et al. A JNK-dependent pathway is required for TNF alpha-induced apoptosis. Cell. 2003; 115:61–70.
25. Hildt E, Oess S. Identification of Grb2 as a novel binding partner of tumor necrosis factor (TNF) receptor I. J ExpMed. 1999; 189: 1707–1714.
26. Madge LA, Pober JS. A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does not activate NFkappaB in human endothelial cells. J Biol Chem. 2000; 275:15458–15465.
27. Adam-Klages S, Adam D, Wiegmann K, et al. FAN, a novel WDrepeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell. 1996; 86:937–947.
28. Madge LA, Li JH, Choi J, Pober JS. Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsin-dependent apoptosis. J Biol Chem. 2003; 278:21295–21306.
29. Li JH, Pober JS. The cathepsin B death pathway contributes to TNF plus IFN-gamma-mediated human endothelial injury. J Immunol. 2005; 175:1858–1866.
30. Feng X, Gaeta ML, Madge LA, et al. Caveolin-1 associates with TRAF2 to form a complex that is recruited to tumor necrosis factor receptors. J Biol Chem. 2001; 276:8341–8349.
31. Zhang R, Xu Y, Ekman N, et al. Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem. 2003; 278:51267–51276.
32. Pan S, An P, Zhang R, et al. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol. 2002; 22:7512–7523.
33. Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood. 1991; 77:542–550.
34. Yoshizumi M, Perrella MA, Burnett JC Jr., Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993; 73:205–209.
35. Messadi DV, Pober JS, Murphy GF. Effects of recombinant gamma-interferon on HLA-DR and DQ expression by skin cells in short-term organ culture. Lab Invest. 1988; 58:61–67.
36. SenBanerjee S, Lin Z, Atkins GB, et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004; 199:1305–1315.
37. Stolpen AH, Guinan EC, Fiers W, Pober JS. Recombinant tumor necrosis factor and immune interferon act singly and in combination toreorganizehumanvascular endothelial cellmonolayers. Am J Pathol. 1986; 123:16–24.
38. Clark P, Pober JS, Kluger MS. J Invest Dermatol. 2007; in press.
39. Lejeune FJ. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest. 2002; 110:433–435.
40. Pober JS. Cytokine-mediated activation of vascular endothelium: physiology and pathology. AmJ Pathol. 1988; 133:426–433.
41. Johnson DR, Pober JS. HLA class I heavy chain gene promoter elements mediating synergy between tumor necrosis factor and interferons. Mol Cell Biol. 1994; 14:1322–1332.
42. Li JH, Kluger MS,Madge LA, et al. Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis. Am J Pathol. 2002; 161:1485–1495.